Drug Information

Drug General Information
Drug ID
D02EEK
Former ID
DNCL002663
Drug Name
J 591 Lu-177
Indication Metastatic prostate cancer; Non-metastatic prostate cancer [ICD9: 140-229, 185; ICD10:C61] Phase 2 [532377]
Company
BZL Biologics
Target and Pathway
Target(s) Glutamate carboxypeptidase II Target Info Modulator [532377]
KEGG Pathway Alanine, aspartate and glutamate metabolism
Metabolic pathways
Vitamin digestion and absorption
NetPath Pathway TCR Signaling Pathway
TNFalpha Signaling Pathway
Reactome Amino acid synthesis and interconversion (transamination)
WikiPathways One Carbon Metabolism
References
Ref 532377Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Sep 15;19(18):5182-91.
Ref 532377Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Sep 15;19(18):5182-91.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.